Updated

Novonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, a potentially lucrative new market, according to a CNBC headline published on November 9, 2026. The coverage is brief and gives no figures, timelines or company statements on the plans. It frames the idea as a possible new opportunity tied to the expanding GLP-1 drug market.